EADV 2022 A digital survey to evaluate the self perceived benefit of a SeS2-1% salicylic shampoo in dermatologists with mild to-moderate scalp seborrheic dermatitis

  • 10min (reading time)
  • Mar. 2023
  • Supported by
  • Laboratoires Vichy

Poster


INTRODUCTION


Seborrheic dermatitis (SD) is a chronic, relapsing inflammatory disorder affecting areas of the head and trunk where sebaceous glands are the most prominent and that evolves with flares and remission.
SD is characterized by episodes of erythematous, scaly lesions of the scalp which can varies from mild to dense, diffuse, adherent flakes and pruritus. When mild scaling without visible inflammation is observed, SD is also named dandruff.
Topical products remain the mainstay of scalp seborrheic dermatitis (SSD) care.
Selenium disulfide (SeS.) is effective in managing both dandruff and SD. It reduces scales, itching, irritation and redness of the scalp. It has shown a full spectrum antimicrobial action against Malassezia yeasts and bacterial species.
To improve the adherence to use and thus to increase therapeutic benefit, a good user perception of treatment is important. Advocating the treatment benefit, based on a self-perceived use by health-care givers may thus be very helpful to convince users.